Cargando…
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495807/ https://www.ncbi.nlm.nih.gov/pubmed/32983475 http://dx.doi.org/10.1002/ccr3.2918 |
| _version_ | 1783582963857883136 |
|---|---|
| author | Tambaro, Francesco Paolo Khazal, Sajad Nunez, Cesar Ragoonanan, Dristhi Tewari, Priti Petropoulos, Demetrios Kebriaei, Partow Wierda, William George Mahadeo, Kris Michael |
| author_facet | Tambaro, Francesco Paolo Khazal, Sajad Nunez, Cesar Ragoonanan, Dristhi Tewari, Priti Petropoulos, Demetrios Kebriaei, Partow Wierda, William George Mahadeo, Kris Michael |
| author_sort | Tambaro, Francesco Paolo |
| collection | PubMed |
| description | The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy. |
| format | Online Article Text |
| id | pubmed-7495807 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74958072020-09-25 Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy Tambaro, Francesco Paolo Khazal, Sajad Nunez, Cesar Ragoonanan, Dristhi Tewari, Priti Petropoulos, Demetrios Kebriaei, Partow Wierda, William George Mahadeo, Kris Michael Clin Case Rep Case Reports The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy. John Wiley and Sons Inc. 2020-05-28 /pmc/articles/PMC7495807/ /pubmed/32983475 http://dx.doi.org/10.1002/ccr3.2918 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Case Reports Tambaro, Francesco Paolo Khazal, Sajad Nunez, Cesar Ragoonanan, Dristhi Tewari, Priti Petropoulos, Demetrios Kebriaei, Partow Wierda, William George Mahadeo, Kris Michael Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy |
| title | Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy |
| title_full | Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy |
| title_fullStr | Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy |
| title_full_unstemmed | Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy |
| title_short | Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy |
| title_sort | complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to cd‐19 chimeric antigen receptor t‐cell therapy |
| topic | Case Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495807/ https://www.ncbi.nlm.nih.gov/pubmed/32983475 http://dx.doi.org/10.1002/ccr3.2918 |
| work_keys_str_mv | AT tambarofrancescopaolo completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT khazalsajad completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT nunezcesar completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT ragoonanandristhi completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT tewaripriti completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT petropoulosdemetrios completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT kebriaeipartow completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT wierdawilliamgeorge completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy AT mahadeokrismichael completeremissioninrefractoryacutelymphoblasticleukemiausingblinatumomabafterfailureofresponsetocd19chimericantigenreceptortcelltherapy |